Indication intelligence, analysis and sector perception

The Biostage (BSTG) Chronicles: Surgeon on trial in Sweden over experimental windpipe transplants

April 28, 2022 2:38pm

BSTG is also ensnared with a terminal death suit involving Paolo Macchiarini

An Italian doctor who made headlines for pioneering windpipe surgery has gone on trial in Sweden, charged with aggravated assault for performing the experimental procedure.

Paolo Macchiarini, who made headlines for pioneering surgery, charged with aggravated assault over procedure

AFP in Stockholm, Wed 27 Apr 2022 10.38 EDT

https://www.theguardian.com/world/2022/apr/27/surgeon-on-trial-in-sweden-over-windpipe-transplants-paolo-macchiarini

But allegations soon emerged that the risky procedure had been carried out on at least one person who had not been critically ill at the time of the operation.

The 63-year-old appeared in court on Wednesday, where he listened to translated audio as prosecutors listed the charges of “aggravated assault” against three patients.

The Karolinska Institute has confirmed that the three individuals have since died, but did not directly link the deaths to the operations.

“Macchiarini has carried out the surgery with complete disregard for science and tried experience,” prosecutor Karin Lundström-Kron told the

Any comment from BSTG, David Green, Interum CEO, Chairman and former (at time) CEO introduced Paolo Macchiarini to Harvard Apparatus Regenerative Tecnology now Biostage (BSTG)

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 28 min ago
RegMed Investors’ (RMi) pre-open: head and knee down

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.